Abstract
Thrombus formation and hemorrhagic complications in patients taking anticoagulants remain one of the most important problems in patients after heart valve replacement, both in the early and late periods after surgery. The article describes a case of successful replacement of phenylin with warfarin in a patient with polymorphism in the CYP2C9 genes based on genetic analysis in the longterm period after aortic valve replacement in a 16-year-old child. The variants of anticoagulant therapy for patients after prosthetic heart valves are considered. Known variants of genetic mutations in the CYP2C9, VKORC1 genes, their variations, prevalence, and effect on warfarin are described. Possible schemes for switching from one anticoagulant to another were evaluated, taking into account resistance. The benefits of genetic testing both in the early and late postoperative period after heart valve replacement were evaluated.
References
- Sychev D.V., Ignatyev I.V., Emelyanov N.V., Milovanova V.V., Kossovskaya A.V., Tashenova A.I., Kukes V.G. CYP2C9 AND VKORC1 gene polymorphism is inessential for bleeding development under conditions of oral application of anticoagulant acenocoumarol in Russ.ian patients at high risk of thromboembolic complications. Bulletin of Experimental Biology and Medicine. 2012; 6: 868–71 (in Russ.).
- Tretyakov A.Yu., Vydrina N.D., Sychev D.A., Kazakov P.E., Gavrisyuk E.V. Kukes I.V. et al. The effect of CYP2C9 AND VKORC1 polymorphism on anticoagulating effect and a maintenance dose of phenindione in patients with atrial fibrillation (results of a pilot study). Clinical Pharmacology and Therapy. 2012; 21 (2): 6–9 (in Russ.).
- Roytman E.V. The use of modern means of drug thrombo-prophylaxis. Lechebnoe Delo (Medical Business). 2005; 2: 49–55 (in Russ.).
- Pengo V., Pegoraro C., Cucchini U., Iliceto S. Worldwide management of oral anticoagulant therapy: the ISAM study. J. Thromb. Thrombolysis. 2006; 21 (1): 73–7. DOI: 10.1007/s11239-006-5580-y. PMID: 16475046.
- Aronson J.K. Meyler's side effects of drugs. The International Encyclopedia of Adverse Drug Reactions and Interactions. 16th edition. Elsevier Science; 2016: 50–1. DOI: 10.1016/B978-0-444-53717-1.00191-8
- Kropacheva E.S., Panchenko E.P., Dobrovolsky A.B., Saidova M.A. Resistance to warfarin in a patient with absolute indications for taking vitamin K antagonists. Atherothrombosis. 2009; 1 (2): 99–104 (in Russ.).
- Nikolaev E.E., Bogdanov A.V., Pavlova S.I., Bogdanova S.M. Clinical case of warfarin resistance in a patient with prosthetic heart valves and the CYP2C9*1*1-VKORC1GG genotype. Cardiology of Belarus. 2020; 12 (3): 432–8. DOI: 10.34883/PI.2020.12.3.011
- Baumgartner H., Falk V., Bax J.J., De Bonis M., Hamm C., Holm P.J. et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur. Heart J. 2017; 38 (36): 2739–91. DOI: 10.1093/eurheartj/ehx391
- Johnson J.A., Caudle K.E., Gong L., Whirl-Carrillo M., Stein C.M., Scott S.A. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin. Pharmacol. Ther. 2017; 102 (3): 397–404. DOI: 10.1002/cpt.668
- Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002; 12 (3): 251–63. DOI: 10.1097/00008571-200204000-00010
- Burkova T.V., Goncharova I.A. Genetic factors influencing the effectiveness and safety of long-term anticoagulant therapy. Cardiovascular Therapy and Prevention. 2013; 12 (3): 89–94 (in Russ.). DOI: 10.15829/1728-8800-2013-3-89-94
- Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh S.L., Farin F.M. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002; 287 (13): 1690–8. DOI: 10.1001/jama.287.13.1690. PMID: 11926893.
- Biswas M., Bendkhale S.R., Deshpande S.P., Thaker S.J., Kulkarni D.V., Bhatia S.J. et al. Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: results of a 5 years audit. Indian Heart J. 2018; 70 (Suppl 3): S13–S19. DOI: 10.1016/j.ihj.2018.02.005
- Aithal G.P., Day C.P., Kesteven P.J., Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999; 353 (9154): 717–9. DOI: 10.1016/S0140-6736(98)04474-2
- Mizzi C., Dalabira E., Kumuthini J., Dzimiri N., Balogh I., Ba¸sak N. et al. A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. PLoS One. 2016; 11 (9): e0162866. DOI: 10.1371/journal.pone.0162866
- Limdi N.A., Arnett D.K., Goldstein J.A., Beasley T.M., McGwin G., Adler B.K. et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin. Pharmacol. Ther. 2008; 83 (2): 312–21. DOI: 10.1038/sj.clpt.6100290
- Lindh J.D., Holm L., Andersson M.L., Rane A. Influence of CYP2C9 genotype on warfarin dose requirements – a systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 2009; 65 (4): 365–75. DOI: 10.1007/s00228-008-0584-5
- Wajih N., Hutson S.M., Owen J., Wallin R. Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle. J. Biol. Chem. 2005; 280 (36): 31603–7. DOI: 10.1074/jbc.M505373200
- Limdi N.A., Wadelius M., Cavallari L., Eriksson N., Crawford D.C., Lee M.T. et al.; International Warfarin Pharmacogenetics Consortium. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010; 115 (18): 3827–34. DOI: 10.1182/blood-2009-12-255992
- Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hörtnagel K., Pelz H.J. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004; 427 (6974): 537–41. DOI: 10.1038/nature02214
- Zhang J., Tian L., Zhang Y., Shen J. The influence of VKORC1 gene polymorphism on warfarin maintenance dosage in pediatric patients: a systematic review and meta-analysis. Thromb Res. 2015; 136 (5): 955–61. DOI: 10.1016/j.thromres.2015.09.018
About the authors
- Anna A. Tokovenko, Pediatric Cardiologist; ORCID
- Valentina N. Shvedunova, Dr. Med. Sc., Head of Department; ORCID
- Anna Yu. Zavarina, Chief Physician of the Children`s Rehabilitation Center; ORCID
- Niyole A. Putyato, Cand. Med. Sc., Head of Department; ORCID
- Angelina V. Kokshina, Pediatric Cardiologist; ORCID
